Lincoln Pharmaceuticals Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Lincoln Pharmaceuticals.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	17.5%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

Improved Earnings Required Before Lincoln Pharmaceuticals Limited (NSE:LINCOLN) Stock's 39% Jump Looks Justified

Dec 05

Lincoln Pharmaceuticals Limited's (NSE:LINCOLN) Business And Shares Still Trailing The Market

Mar 14

Does Lincoln Pharmaceuticals (NSE:LINCOLN) Deserve A Spot On Your Watchlist?

Nov 04

Lincoln Pharmaceuticals' (NSE:LINCOLN) Dividend Will Be ₹1.50

Sep 14

Lincoln Pharmaceuticals (NSE:LINCOLN) Is Paying Out A Dividend Of ₹1.50

Aug 31

Lincoln Pharmaceuticals' (NSE:LINCOLN) Dividend Will Be ₹1.50

Sep 12

Lincoln Pharmaceuticals (NSE:LINCOLN) Is Due To Pay A Dividend Of ₹1.50

Aug 29

If You Like EPS Growth Then Check Out Lincoln Pharmaceuticals (NSE:LINCOLN) Before It's Too Late

Feb 14

Should You Be Adding Lincoln Pharmaceuticals (NSE:LINCOLN) To Your Watchlist Today?

Aug 16

Here's Why I Think Lincoln Pharmaceuticals (NSE:LINCOLN) Is An Interesting Stock

May 06

Is Lincoln Pharmaceuticals Limited (NSE:LINCOLN) A Smart Choice For Dividend Investors?

Apr 03

Does Lincoln Pharmaceuticals (NSE:LINCOLN) Have A Healthy Balance Sheet?

Mar 15

Could The Market Be Wrong About Lincoln Pharmaceuticals Limited (NSE:LINCOLN) Given Its Attractive Financial Prospects?

Feb 28

Insider Buying: The Lincoln Pharmaceuticals Limited (NSE:LINCOLN) Whole Time Director Just Bought 15% More Shares

Feb 12

Does Lincoln Pharmaceuticals (NSE:LINCOLN) Deserve A Spot On Your Watchlist?

Feb 01

Lincoln Pharmaceuticals (NSE:LINCOLN) Shareholders Booked A 27% Gain In The Last Five Years

Jan 19

Trade Alert: The Whole Time Director Of Lincoln Pharmaceuticals Limited (NSE:LINCOLN), Munjal Patel, Has Just Spent ₹20m Buying 9.2% More Shares

Jan 06

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lincoln Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NSEI:LINCOLN - Analysts future estimates and past financials data (INR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2024	5,974	966	253	647	N/A
6/30/2024	5,922	980	N/A	N/A	N/A
3/31/2024	5,805	933	236	632	N/A
12/31/2023	5,505	873	N/A	N/A	N/A
9/30/2023	5,378	808	662	798	N/A
6/30/2023	5,225	769	N/A	N/A	N/A
3/31/2023	5,103	729	250	393	N/A
12/31/2022	5,004	714	N/A	N/A	N/A
9/30/2022	4,866	674	-23	328	N/A
6/30/2022	4,734	667	N/A	N/A	N/A
3/31/2022	4,721	694	306	761	N/A
12/31/2021	4,491	709	N/A	N/A	N/A
9/30/2021	4,440	668	411	675	N/A
6/30/2021	4,426	647	N/A	N/A	N/A
3/31/2021	4,242	623	605	693	N/A
12/31/2020	4,231	586	N/A	N/A	N/A
9/30/2020	4,068	560	837	891	N/A
6/30/2020	3,935	540	N/A	N/A	N/A
3/31/2020	3,865	514	677	754	N/A
12/31/2019	3,873	510	N/A	N/A	N/A
9/30/2019	3,733	492	N/A	N/A	N/A
6/30/2019	3,632	453	N/A	N/A	N/A
3/31/2019	3,661	487	379	528	N/A
12/31/2018	3,542	470	N/A	N/A	N/A
9/30/2018	3,238	495	N/A	N/A	N/A
6/30/2018	3,109	458	N/A	N/A	N/A
3/31/2018	3,606	346	N/A	266	N/A
12/31/2017	4,463	281	N/A	N/A	N/A
9/30/2017	4,364	231	N/A	N/A	N/A
6/30/2017	4,063	206	N/A	N/A	N/A
3/31/2017	3,603	281	N/A	250	N/A
12/31/2016	3,650	301	N/A	N/A	N/A
9/30/2016	3,995	301	N/A	N/A	N/A
6/30/2016	4,245	281	N/A	N/A	N/A
3/31/2016	4,002	237	N/A	448	N/A
12/31/2015	3,504	219	N/A	N/A	N/A
9/30/2015	3,100	180	N/A	N/A	N/A
6/30/2015	2,926	183	N/A	N/A	N/A
3/31/2015	2,661	150	N/A	246	N/A
12/31/2014	2,545	135	N/A	N/A	N/A
9/30/2014	2,420	142	N/A	N/A	N/A
6/30/2014	2,181	106	N/A	N/A	N/A
3/31/2014	2,107	107	N/A	46	N/A
12/31/2013	2,011	140	N/A	N/A	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if LINCOLN's forecast earnings growth is above the savings rate (6.7%).

Earnings vs Market: Insufficient data to determine if LINCOLN's earnings are forecast to grow faster than the Indian market

High Growth Earnings: Insufficient data to determine if LINCOLN's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if LINCOLN's revenue is forecast to grow faster than the Indian market.

High Growth Revenue: Insufficient data to determine if LINCOLN's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if LINCOLN's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/20 04:08
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Lincoln Pharmaceuticals Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Kameswari V. S. Chavali	FirstCall Research

Lincoln Pharmaceuticals Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Improved Earnings Required Before Lincoln Pharmaceuticals Limited (NSE:LINCOLN) Stock's 39% Jump Looks Justified

New major risk - Share price stability

Investor sentiment improves as stock rises 21%

Lincoln Pharmaceuticals' (NSE:LINCOLN) Earnings Are Of Questionable Quality

Second quarter 2025 earnings released: EPS: ₹13.15 (vs ₹13.81 in 2Q 2024)

Lincoln Pharmaceuticals Limited to Report Q2, 2025 Results on Nov 14, 2024

Lincoln Pharmaceuticals Limited Declarers Dividend for the Financial Year 2023-2024

Lincoln Pharmaceuticals' (NSE:LINCOLN) Dividend Will Be Increased To ₹1.80

Do Lincoln Pharmaceuticals' (NSE:LINCOLN) Earnings Warrant Your Attention?

Dividend increased to ₹1.80

Lincoln Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2024

Lincoln Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2024

First quarter 2025 earnings released: EPS: ₹11.82 (vs ₹9.49 in 1Q 2024)

Lincoln Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 08, 2024

Lincoln Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 08, 2024

Whole Time Director recently bought ₹20m worth of stock

Full year 2024 earnings released: EPS: ₹46.58 (vs ₹36.40 in FY 2023)

Lincoln Pharmaceuticals Limited Recommends Dividend for the Year Ended March 31, 2024

New minor risk - Insider selling

Now 20% overvalued

Now 22% overvalued

Now 24% overvalued

Lincoln Pharmaceuticals Limited's (NSE:LINCOLN) Business And Shares Still Trailing The Market

Investor sentiment improves as stock rises 15%

Lincoln Pharmaceuticals Limited Announces Resignation of Meha Patel as Non-Executive Independent women Director

Insider recently bought ₹13m worth of stock

Third quarter 2024 earnings released: EPS: ₹14.00 (vs ₹10.79 in 3Q 2023)

Lincoln Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 08, 2024

Does Lincoln Pharmaceuticals (NSE:LINCOLN) Deserve A Spot On Your Watchlist?

Second quarter 2024 earnings released: EPS: ₹13.81 (vs ₹11.84 in 2Q 2023)

Lincoln Pharmaceuticals Limited Declares Dividend for the Financial Year 2022-23

Lincoln Pharmaceuticals' (NSE:LINCOLN) Dividend Will Be ₹1.50

Upcoming dividend of ₹1.50 per share at 0.3% yield

Lincoln Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 14, 2024

Lincoln Pharmaceuticals (NSE:LINCOLN) Is Paying Out A Dividend Of ₹1.50

Whole Time Director recently bought ₹15m worth of stock

First quarter 2024 earnings released: EPS: ₹9.49 (vs ₹7.49 in 1Q 2023)

Whole Time Director recently bought ₹15m worth of stock

Full year 2023 earnings released: EPS: ₹36.40 (vs ₹34.63 in FY 2022)

Lincoln Pharmaceuticals Limited Approves the Resignation of Anand A. Patel from the Position of Whole Time Director as Well as Director of the Company

Investor sentiment improves as stock rises 15%

Lincoln Pharmaceuticals Limited to Report Q4, 2023 Results on May 25, 2023

Whole Time Director recently bought ₹5.0m worth of stock

Third quarter 2023 earnings released: EPS: ₹10.79 (vs ₹8.79 in 3Q 2022)

Lincoln Pharmaceuticals Limited to Report Q3, 2023 Results on Feb 09, 2023

Lincoln Pharmaceuticals Limited Informs About Demise of Shri Ishwarlal Ambalal Patel Independent Director

MD & Whole Time Director recently bought ₹20m worth of stock

MD & Whole Time Director recently bought ₹9.9m worth of stock

Less than half of directors are independent

Lincoln Pharmaceuticals Limited Appoints Trusha Shah as Company Secretary and Compliance Officer

Lincoln Pharmaceuticals Limited Approves to Declare Dividend for the Financial Year 2021-22

Lincoln Pharmaceuticals' (NSE:LINCOLN) Dividend Will Be ₹1.50

Upcoming dividend of ₹1.50 per share

Lincoln Pharmaceuticals Limited Proposes to Declare Dividend for the Financial Year 2021-2022

Lincoln Pharmaceuticals Limited Proposes to Declare Dividend for the Financial Year 2021-2022

Lincoln Pharmaceuticals (NSE:LINCOLN) Is Due To Pay A Dividend Of ₹1.50

Lincoln Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2022

Lincoln Pharmaceuticals Limited Approves Appointment of Anand A. Patel as an Additional and Whole Time Director

First quarter 2023 earnings released: EPS: ₹7.49 (vs ₹8.85 in 1Q 2022)

Lincoln Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 09, 2022

Lincoln Pharmaceuticals Limited Announces Resignation of Niren A. Desai as Company Secretary / Compliance Officer, with Effect from July 19, 2022

Board Member recently bought ₹20m worth of stock

Whole Time Director recently bought ₹20m worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Lincoln Pharmaceuticals Limited Recommends Dividend for the Year Ended March 31, 2022

Less than half of directors are independent

Whole Time Director recently bought ₹6.0m worth of stock

If You Like EPS Growth Then Check Out Lincoln Pharmaceuticals (NSE:LINCOLN) Before It's Too Late

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Lincoln Pharmaceuticals Limited to Report Q3, 2022 Results on Feb 10, 2022

Board Member recently bought ₹8.2m worth of stock

Lincoln Pharmaceuticals Limited (BSE:531633) acquired plant in Mehsana, Gujarat for INR 300 million.

MD & Whole Time Director recently bought ₹15m worth of stock

Investor sentiment improved over the past week

Board Member recently bought ₹11m worth of stock